Literature DB >> 9683071

Serologic response of horses to the structural proteins of equine arteritis virus.

N J MacLachlan1, U B Balasuriya, J F Hedges, T M Schweidler, W H McCollum, P J Timoney, P J Hullinger, J F Patton.   

Abstract

Equine arteritis virus (EAV) is the causative agent of equine viral arteritis, an apparently emerging disease of equids. In this study, the antibody response of horses to the structural proteins of EAV was evaluated using gradient-purified EAV virions and baculovirus-expressed recombinant EAV structural proteins (G(L), G(S), M, N) as antigens in a Western immunoblotting assay. Thirty-three sera from horses that previously had been naturally or experimentally infected with EAV were evaluated, including samples from mares, geldings, and both persistently and nonpersistently infected stallions. Sera also were evaluated from 4 horses that had been vaccinated with the commercial modified live EAV vaccine. The data suggest that the serologic response of individual horses to EAV may vary with the infecting virus strain and duration of infection. The M protein was most consistently recognized by the various serum samples, whereas the response to the N and G(L) proteins was variable and the G(S) protein was bound by only 1 serum sample. The immunoblotting assay definitively established the protein specificity of the humoral response of horses to EAV; however, it clearly is less sensitive than the standard serum neutralization (SN) test--2 of the 37 sera that were seropositive by the SN test failed to react in the immunoblot assay with any EAV structural protein. Furthermore, the G(L) protein expresses the known neutralization determinants of EAV, yet only 22 of the 37 sera that had SN antibodies bound the G(L) protein in the immunoblotting assay. Information from this study will assist ongoing efforts to develop improved methods for the serologic diagnosis of EAV infection of horses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683071     DOI: 10.1177/104063879801000302

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  21 in total

1.  Arterivirus discontinuous mRNA transcription is guided by base pairing between sense and antisense transcription-regulating sequences.

Authors:  G van Marle; J C Dobbe; A P Gultyaev; W Luytjes; W J Spaan; E J Snijder
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Monoclonal antibodies directed against conserved epitopes on the nucleocapsid protein and the major envelope glycoprotein of equine arteritis virus.

Authors:  E Weiland; S Bolz; F Weiland; W Herbst; M J Raamsman; P J Rottier; A A De Vries
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Genetic manipulation of arterivirus alternative mRNA leader-body junction sites reveals tight regulation of structural protein expression.

Authors:  A O Pasternak; A P Gultyaev; W J Spaan; E J Snijder
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  A complex zinc finger controls the enzymatic activities of nidovirus helicases.

Authors:  Anja Seybert; Clara C Posthuma; Leonie C van Dinten; Eric J Snijder; Alexander E Gorbalenya; John Ziebuhr
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Development and characterization of an infectious cDNA clone of the modified live virus vaccine strain of equine arteritis virus.

Authors:  Jianqiang Zhang; Yun Young Go; Chengjin M Huang; Barry J Meade; Zhengchun Lu; Eric J Snijder; Peter J Timoney; Udeni B R Balasuriya
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

6.  Importance of M-protein C terminus as substrate antigen for serodetection of equine arteritis virus infection.

Authors:  Célia Jeronimo; Denis Archambault
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

7.  Arterivirus Nsp1 modulates the accumulation of minus-strand templates to control the relative abundance of viral mRNAs.

Authors:  Danny D Nedialkova; Alexander E Gorbalenya; Eric J Snijder
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

8.  Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.

Authors:  Adriaan H de Wilde; Yanhua Li; Yvonne van der Meer; Grégoire Vuagniaux; Robert Lysek; Ying Fang; Eric J Snijder; Martijn J van Hemert
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

9.  Persistent equine arteritis virus infection in HeLa cells.

Authors:  Jianqiang Zhang; Peter J Timoney; N James MacLachlan; William H McCollum; Udeni B R Balasuriya
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

10.  Development of a fluorescent-microsphere immunoassay for detection of antibodies specific to equine arteritis virus and comparison with the virus neutralization test.

Authors:  Yun Young Go; Susan J Wong; Adam J Branscum; Valerie L Demarest; Kathleen M Shuck; Mary L Vickers; Jianqiang Zhang; William H McCollum; Peter J Timoney; Udeni B R Balasuriya
Journal:  Clin Vaccine Immunol       Date:  2007-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.